Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study

Diabetes, Obesity and Metabolism

Volumn 20, Issue 2, 2018, Pages 438-442

  Shibuya, Takashi ^a   Fushimi, Nobutoshi ^a   Kawai, Miyuka ^a   Yoshida, Yohei ^a   Hachiya, Hiroki ^a   Ito, Shun ^a   Kawai, Hiromi ^a   Ohashi, Noritsugu ^a   Mori, Akihiro ^a  

^a Ichinomiya Nishi Hospital   (Japan)

Author keywords

antidiabetic drug; fatty liver; SGLT2 inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LUSEOGLIFLOZIN; METFORMIN; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPOTROPIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; SORBITOL;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG MECHANISM; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTRA-ABDOMINAL FAT; LIPID STORAGE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; BODY WEIGHT LOSS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECT; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; OBESITY; ORGAN SIZE; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

ADIPOSITY; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIPOTROPIC AGENTS; LIVER; MALE; MEMBRANE TRANSPORT MODULATORS; METFORMIN; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGAN SIZE; PILOT PROJECTS; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY; WEIGHT LOSS;

EID: 85040734374     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13061     Document Type: Article

References (18)

1. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141-1145.
2. Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011;46:1230-1237.
3. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2009;129:113-121.
4. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-2307.
5. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537-544.
6. Dutour A, Abdesselam I, Ancel P, et al. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18:882-891.
7. Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014;30:1245-1255.
8. Pickhardt PJ, Park SH, Hahn L, Lee SG, Bae KT, Specificity YES. Of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2007;22:1075-1082.
9. Sakai S, Kaku K, Seino Y, et al. Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials. Clin Ther. 2016;38:843-862.
10. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;30:999-1009.
11. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-517.
12. Honda Y, Imajo K, Kato T, et al. The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS One. 2016;11:e0146337.
13. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395-420.
14. Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP. Nature. 2013;494:256-260.
15. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 2011;13(suppl 1):89-94.
16. Qiang S, Nakatsu Y, Seno Y, et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr. 2015;7:104.
17. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364-377.
18. Consoli A, Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes Obes Metab. 2013;15:967-977.